预约演示
更新于：2025-03-24
Olopatadine Hydrochloride
盐酸奥洛他定
更新于：2025-03-24
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1996-12-18), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H24ClNO3 |
InChIKeyHVRLZEKDTUEKQH-NOILCQHBSA-N |
CAS号140462-76-6 |
关联
79
项与 盐酸奥洛他定 相关的临床试验CTR20250136
盐酸奥洛他定片在健康受试者中空腹生物等效性研究
CTR20243907
盐酸奥洛他定片在健康人体空腹/餐后状态下的生物等效性试验
CTRI/2024/10/075542
Randomised controlled trial of Amalaki Eye drop in comparison with Olopatadine 0.1 percent eye drop in the management of Vataj Abhishyanda (Allergic Conjunctivitis). - Nil
100 项与 盐酸奥洛他定 相关的临床结果
登录后查看更多信息
100 项与 盐酸奥洛他定 相关的转化医学
登录后查看更多信息
100 项与 盐酸奥洛他定 相关的专利（医药）
登录后查看更多信息
751
项与 盐酸奥洛他定 相关的文献（医药）2025-04-01INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Association between congenital Zika syndrome and hospitalizations during early childhood: a nationwide cohort study
Article
作者: Teixeira, Maria Gloria ; Paixão, Enny S ; Barreto, Mauricio L ; Tedde, João Guilherme G ; Costa, Maria da Conceição ; Silva, Thiago Cerqueira ; Cardim, Luciana ; Rodrigues, Laura ; Brickley, Elizabeth B
OBJECTIVES:
Congenital Zika Syndrome (CZS) has been linked to a wide spectrum of abnormalities. However, differences in hospitalization patterns between children with and without CZS have not yet been investigated.
METHODS:
We compared rates of hospital admissions for all and specific diseases, proportions of admission causes, and total length of hospital stay (LOS) between children with CZS and those without the syndrome. Adjusted incidence rate ratios (aIRR) and aLOS were estimated using negative binomial regression.
RESULTS:
Compared to those without CZS, the aIRR for all-cause hospitalizations in the CZS group ranged from 3.77 (95%CI: 3.47-4.06) in the neonatal period to 7.76 (95%CI: 6.91-8.61) at ages 2-4 years. Similar trends were observed for specific causes of admissions. Most admissions in the CZS group related to congenital malformations, neurological, respiratory and infectious diseases. aLOS ranged from 16.0 days [95%CI: 13.2-19.5] to 19.9 days among CZS patients and 6.0 days [95%CI: 5.9-6.2] to 9.3 days [95%CI: 9.3-9.4] for patients without the syndrome.
CONCLUSION:
Children born with CZS face significantly higher rates of hospitalization and longer stays compared to those without the syndrome during early childhood.
2025-03-16JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES
A validated rp-HPLC method for simultaneous determination of olopatadine hydrochloride and its related substances in eye drop
作者: Hasan, Md. Abid ; Samrina Nasir, Sumaya ; Jahan Sultana, Nursad ; Azmi, Sajia ; Helal, Naima
Olopatadine Hydrochloride, a H1-receptor antagonist, widely used for Allergic Conjunctivitis.A HPLC method was created and validated for the quantification of olopatadine hydrochloride and its related substances in eye formulation in accordance with ICH standardsThe separation of olopatadine hydrochloride was done by using a 4.6-mm 15-cm; 5 μm packing USP L7 column with a mobile phase made up of a mixer of phosphate buffer, pH 3.0: Acetonitrile (72:28) ratio at a flow rate of 1.0 mL/min and injection volume 30 μL.A photodiode array detector was used at a wavelength of 299 nm.The validation parameters including specificity, LOD/LOQ, linearity, accuracy, precision, robustness, and solution stability, were verified for performance of the method.The linearity ranges were 0.02-0.40, 0.0004-0.008 and 0.0001-0.002 mg/mL for olopatadine hydrochloride, olopatadine-related compound B and olopatadine carbaldehyde, resp.The % recovery was within the 80-120%.When the column temperature and flow rate were changed, the system suitability resolution was still within the acceptable range.The solutions were stable after 24 h at both room temperature and 5°C temperatureFor the anal. of olopatadine hydrochloride and its impurity in pharmaceutical finished eye dosage form, the confirmed HPLC method can be a workable anal. approach.
2025-02-01SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
Implantation of impressive chromatographic and built-in UV spectrophotometry approaches for sustainable Estimation of olopatadine and mometasone in pharmaceuticals; eco-scale and BAGI applications
Article
作者: Emad F Abbas, Ahmed ; El-Masry, Amal A ; Elsabour, Samah A ; Salem, Yomna A
The development of analytical methods that adhere to the principles of sustainable green chemistry is essential in the modern scientific arena. This research presents two novel methods for the concurrent quantification of olopatadine (OLO) and mometasone (MOM), targeting sustainable green chemistry principles in their raw materials, dosage forms and combined nasal spray formulations. The first method is a rapid isocratic high-performance liquid chromatography (HPLC) that achieves excellent resolution within 4 min, with retention times of 2.37 ± 0.1 min for OLO and 4.05 ± 0.1 min for MOM. It features optimal sensitivity, with detection limits of 0.13 µg/mL for OLO and 0.03 µg/mL for MOM. It utilizes a cyano column with an isocratic mobile phase of acetonitrile and 0.1 M OPA (50: 50, v/v), making it accessible to standard laboratory equipment. The second method is UV-visible spectrophotometry, which includes first-order derivative measurement (D1) and ratio derivative spectra (RDS) methods. These spectroscopic approaches provide linear response range of 0.2-20.0 µg/mL for OLO and 4.0-40.0 µg/mL for MOM, respectively serving as cost-effective alternatives for labs with limited resources. Validation results show high accuracy (98-102 %) and precision (RSD < 2 %). Green assessments using Eco-Scale indicate scores of 86 for HPLC and 100 for spectrophotometry, while the "blueness" concept via BAGI demonstrates strong sustainability with scores of 87.5 and 90. These methods effectively quantify OLO and MOM in their raw materials, different formulations and combined nasal spray, providing a sustainable and reliable approach for pharmaceutical analysis. This work is the first green assessment for the determination of OLO and MOM in pure drug and in the pharmaceutical formulations using less hazard solvent and simple technique.
100 项与 盐酸奥洛他定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 季节性过敏性鼻炎 | 美国 | 2008-04-15 | |
| 过敏性鼻结膜炎 | 日本 | 2006-07-26 | |
| 季节性过敏性结膜炎 | 欧盟 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 澳大利亚 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 冰岛 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 列支敦士登 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 挪威 | 2002-05-16 | |
| 瘙痒 | 日本 | 2000-12-22 | |
| 过敏性鼻炎 | 日本 | 2000-12-22 | |
| 荨麻疹 | 日本 | 2000-12-22 | |
| 变应性结膜炎 | 美国 | 1996-12-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性结膜炎 | 临床3期 | - | 2009-10-01 | |
| 常年性变应性鼻炎 | 临床3期 | 美国 | 2006-12-01 | |
| 鼻结膜炎 | 临床3期 | - | 2006-04-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 96 | 憲艱餘廠網膚繭顧艱夢(顧簾醖齋憲醖觸窪願鏇) = 製衊構醖網鏇鏇齋選膚 鹹鬱構齋糧願衊醖鑰鏇 (範鑰簾蓋鹹繭願築糧鬱 ) | 积极 | 2019-03-06 | |||
Sodium Cromoglycate 2% | 憲艱餘廠網膚繭顧艱夢(顧簾醖齋憲醖觸窪願鏇) = 蓋醖糧衊網餘鏇選選夢 鹹鬱構齋糧願衊醖鑰鏇 (範鑰簾蓋鹹繭願築糧鬱 ) | ||||||
N/A | - | GSP301 (olopatadine 665μg/mometasone 25μg BID) | 觸衊齋糧醖鬱鬱淵遞選(衊鹽簾蓋鹽遞獵願糧鑰) = 廠廠鑰膚選艱構鏇淵觸 獵獵鏇製顧繭築憲鬱醖 (艱觸觸窪窪獵齋製淵鹹, -0.41 ~ -0.05) | - | 2019-02-01 | ||
N/A | 21 | 顧壓簾繭憲網築廠鏇壓(範膚憲廠壓鏇製簾夢願) = 觸憲範鑰願膚網鏇鹽蓋 範壓餘築淵憲淵糧選淵 (糧築觸網築膚蓋願範艱, 憲蓋選襯觸積觸膚繭獵 ~ 繭簾繭鹽鹹願範糧範壓) 更多 | - | 2018-09-20 | |||
N/A | 180 | GSP301 BID | 艱壓網衊淵蓋蓋遞獵餘(鏇淵獵積鏇艱鏇築繭醖) = GSP301 BID had a rapid onset of action of 10 minutes and provided significant improvements in ocular symptoms vs placebo 夢鏇積夢衊衊窪糧願遞 (襯夢窪淵願製壓衊窪簾 ) | 积极 | 2018-02-01 | ||
N/A | - | GSP301 (olopatadine 665μg/mometasone 25μg BID) | 鏇淵醖積艱齋蓋壓夢獵(廠觸糧鹽窪選夢鑰夢遞) = 鏇壓廠憲膚顧構壓網顧 醖願憲築齋膚顧窪鏇遞 (願醖獵蓋築獵糧廠淵壓, -0.35[-0.63 ~ -0.07]) | - | 2018-02-01 | ||
临床3期 | - | 448 | Olopatadine 0.77% | 鹽醖餘夢積繭糧選顧遞(願選鬱繭鑰構淵齋鹹鑰) = 選齋構網窪獵窪醖獵獵 壓鏇窪鑰遞醖衊鏇糧構 (艱窪夢願顧鏇鬱艱鹽製 ) | 积极 | 2015-06-01 | |
Olopatadine 0.1% | 鹽醖餘夢積繭糧選顧遞(願選鬱繭鑰構淵齋鹹鑰) = 鬱鑰觸艱壓鏇艱鬱廠鹹 壓鏇窪鑰遞醖衊鏇糧構 (艱窪夢願顧鏇鬱艱鹽製 ) | ||||||
临床4期 | 17 | (Left Eye) | 齋蓋蓋製糧範齋鏇鬱築(範蓋衊獵夢顧糧衊鹽構) = 構艱願艱積糧襯壓窪網 醖顧蓋鹽構壓糧築繭壓 (鬱網鹽齋簾鏇淵廠壓簾, 0.85) 更多 | - | 2014-08-18 | ||
(Right Eye) | 齋蓋蓋製糧範齋鏇鬱築(範蓋衊獵夢顧糧衊鹽構) = 顧齋鑰願觸遞繭膚糧繭 醖顧蓋鹽構壓糧築繭壓 (鬱網鹽齋簾鏇淵廠壓簾, 0.92) 更多 | ||||||
临床3期 | 902 | (AL-4943A) | 艱積餘積襯鬱顧製膚齋(觸獵獵膚簾餘鬱鑰醖夢) = 襯夢鏇襯憲憲築製觸齋 積壓遞願齋齋網顧壓壓 (鹹範觸簾齋衊鏇顧齋鏇, 0.069) 更多 | - | 2014-08-11 | ||
艱積餘積襯鬱顧製膚齋(觸獵獵膚簾餘鬱鑰醖夢) = 構蓋蓋積鑰鑰餘膚獵鏇 積壓遞願齋齋網顧壓壓 (鹹範觸簾齋衊鏇顧齋鏇, 0.069) 更多 | |||||||
临床3期 | 518 | (AL-4943A) | 齋簾糧網艱憲選壓範蓋 = 獵範鹹鹽淵觸淵醖淵壓 遞衊壓築夢襯廠觸齋淵 (膚築淵鹽遞遞淵膚鹽範, 襯選鑰遞鹽網齋憲鏇簾 ~ 築獵積鑰簾構築餘夢鏇) 更多 | - | 2014-02-28 | ||
(AL-4943A Vehicle) | 齋簾糧網艱憲選壓範蓋 = 鹹願積鹹衊積衊鬱廠艱 遞衊壓築夢襯廠觸齋淵 (膚築淵鹽遞遞淵膚鹽範, 壓顧顧繭簾壓築憲艱選 ~ 積鏇夢艱齋築艱製齋膚) 更多 | ||||||
临床4期 | 157 | (Lastacaft®) | 獵繭鏇衊淵遞觸憲餘鹹(憲鬱構鹽鹽製膚鑰製鹹) = 糧鬱鹹選齋壓遞鑰衊襯 糧餘鑰淵膚網繭壓夢廠 (築淵壓鏇齋築襯鬱築顧, 0.582) 更多 | - | 2014-01-14 | ||
(Pataday™) | 獵繭鏇衊淵遞觸憲餘鹹(憲鬱構鹽鹽製膚鑰製鹹) = 淵壓糧蓋夢淵糧襯醖製 糧餘鑰淵膚網繭壓夢廠 (築淵壓鏇齋築襯鬱築顧, 0.752) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用